# An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)

> **NCT04919616** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai OriginCell Therapeutics Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** TILs（Tumor Infiltrating Lymphocytes）

## Key facts

- **NCT ID:** NCT04919616
- **Lead sponsor:** Shanghai OriginCell Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-15
- **Primary completion:** 2023-06-15
- **Final completion:** 2025-06-15
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04919616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04919616, "An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04919616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*